secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2024-01-31T23:59:59+00:00
Accession:  0001157523-24-000137
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva FY2023 revenue $15.8B, Non-GAAP EPS $2.56; AUSTEDO $1.2B; 2024 guidance issued; revises prior results
--------------------------------------------------------------------------------

- Full-year 2023 revenues $15,846M, up 7% in local currency; Q4 revenues $4,465M.
- Non-GAAP diluted EPS $2.56 (vs $2.52 in 2022); GAAP net loss $(0.50) per share.
- AUSTEDO annual revenue exceeded $1.2B (+28%); AJOVY $435M (+16%).
- 2024 outlook: revenue $15.7-$16.3B, Non-GAAP EPS $2.20-$2.50, free cash flow $1.7-$2.0B.
- Revision: $132M contingent consideration understatement; material weakness in internal controls identified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000115752324000137/0001157523-24-000137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000115752324000137/a53889897.htm
  HTML page:      https://secwatch.observer/filing/0001157523-24-000137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer